- Home
- SXTP vs REVB Comparison
SXTP vs REVB Comparison
Compare SXTP & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- REVB
- Stock Information
- Founded
- SXTP 2010
- REVB 2020
- Country
- SXTP United States
- REVB United States
- Employees
- SXTP N/A
- REVB N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- SXTP Health Care
- REVB Health Care
- Exchange
- SXTP Nasdaq
- REVB Nasdaq
- Market Cap
- SXTP 2.7M
- REVB 2.8M
- IPO Year
- SXTP 2023
- REVB N/A
- Fundamental
- Price
- SXTP $2.95
- REVB $2.92
- Analyst Decision
- SXTP Hold
- REVB
- Analyst Count
- SXTP 1
- REVB 0
- Target Price
- SXTP N/A
- REVB N/A
- AVG Volume (30 Days)
- SXTP 4.8M
- REVB 146.9K
- Earning Date
- SXTP 05-14-2025
- REVB 05-09-2025
- Dividend Yield
- SXTP N/A
- REVB N/A
- EPS Growth
- SXTP N/A
- REVB N/A
- EPS
- SXTP N/A
- REVB N/A
- Revenue
- SXTP $681,345.00
- REVB N/A
- Revenue This Year
- SXTP $95.50
- REVB N/A
- Revenue Next Year
- SXTP $80.78
- REVB N/A
- P/E Ratio
- SXTP N/A
- REVB N/A
- Revenue Growth
- SXTP 168.70
- REVB N/A
- 52 Week Low
- SXTP $1.41
- REVB $2.36
- 52 Week High
- SXTP $36.00
- REVB $60.80
- Technical
- Relative Strength Index (RSI)
- SXTP 56.45
- REVB 45.77
- Support Level
- SXTP $2.48
- REVB $2.76
- Resistance Level
- SXTP $3.45
- REVB $3.62
- Average True Range (ATR)
- SXTP 0.70
- REVB 0.41
- MACD
- SXTP 0.02
- REVB 0.02
- Stochastic Oscillator
- SXTP 47.63
- REVB 34.12
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).